UPDATE: UBS Maintains Buy On Allergan, Raises Tgt To $189 'based on ABBV Target Price of $79 and assuming deal closes' In 1Q'20;Firm Notes 'ABBV/AGN has sufficiently addressed possible anti-trust issues with the announced divestitures of Zenpep and Creon'